Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (111-120 of 232) with videos related to

Pageof 24
Sort By:
Pediatric Blood & Cancer|July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyOrren Beaty, Stacey Berg, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Investigational New Drugs|September 24, 2009
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumorsCharles J Nock, Joanna M Brell, Joseph A Bokar, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2020
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration markerAnand Joshi, Jianxia Guo, Julianne L Holleran, et al.
Neuro-Oncology|August 22, 2008
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I studyKristin A Bradley, Ian F Pollack, Joel M Reid, et al.
JCO Precision Oncology|February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid TumorsYiduo Hu, Azeet Narayan, Yunshan Xu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerJoyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaJoanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2008
A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumorsWilliam R Schelman, Sherry Morgan-Meadows, Rebecca Marnocha, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2004
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neckMatthew M Cooney, Kou-Yi Tserng, Vinit Makar, et al.
Pageof 24

Showing results (111-120 of 232) with videos related to

Sort By:
Pageof 24
Pediatric Blood & Cancer|July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyOrren Beaty, Stacey Berg, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Investigational New Drugs|September 24, 2009
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumorsCharles J Nock, Joanna M Brell, Joseph A Bokar, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2020
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration markerAnand Joshi, Jianxia Guo, Julianne L Holleran, et al.
Neuro-Oncology|August 22, 2008
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I studyKristin A Bradley, Ian F Pollack, Joel M Reid, et al.
JCO Precision Oncology|February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid TumorsYiduo Hu, Azeet Narayan, Yunshan Xu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerJoyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaJoanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2008
A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumorsWilliam R Schelman, Sherry Morgan-Meadows, Rebecca Marnocha, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2004
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neckMatthew M Cooney, Kou-Yi Tserng, Vinit Makar, et al.
Pageof 24